Edwards Lifesciences (0REN) Ratios
Edwards Lifesciences Ratios
GB:0REN's free cash flow for Q2 2026 was $585.00M. For the 2026 fiscal year, GB:0REN's free cash flow was decreased by $-66.90M and operating cash flow was $651.90M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.72 | 4.18 | 3.38 | 3.03 | 3.08 |
| Quick Ratio | 3.09 | 3.45 | 2.62 | 2.17 | 2.38 |
| Cash Ratio | 1.62 | 2.02 | 0.95 | 0.75 | 0.84 |
| Solvency Ratio | 0.37 | 1.45 | 0.59 | 0.68 | 0.62 |
| Operating Cash Flow Ratio | 0.88 | 0.36 | 0.75 | 1.19 | 1.68 |
| Short-Term Operating Cash Flow Coverage | 65.11 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 3.38B | $ 3.29B | $ 1.39B | $ 610.00M | $ 514.00M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.05 | 0.05 | 0.07 | 0.08 | 0.08 |
| Debt-to-Equity Ratio | 0.07 | 0.07 | 0.10 | 0.12 | 0.12 |
| Debt-to-Capital Ratio | 0.06 | 0.07 | 0.09 | 0.11 | 0.11 |
| Long-Term Debt-to-Capital Ratio | 0.05 | 0.06 | 0.08 | 0.09 | 0.09 |
| Financial Leverage Ratio | 1.32 | 1.31 | 1.41 | 1.43 | 1.46 |
| Debt Service Coverage Ratio | 49.49 | 79.34 | 78.55 | 65.45 | 68.19 |
| Interest Coverage Ratio | 0.00 | 69.63 | 81.10 | 64.98 | 64.94 |
| Debt to Market Cap | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Interest Debt Per Share | 1.21 | 1.20 | 1.16 | 1.16 | 1.15 |
| Net Debt to EBITDA | -1.56 | -1.36 | -0.29 | -0.04 | -0.09 |
| Profitability Margins | |||||
| Gross Profit Margin | 78.13% | 79.46% | 79.30% | 78.31% | 76.57% |
| EBIT Margin | 20.98% | 28.82% | 27.74% | 33.32% | 33.00% |
| EBITDA Margin | 23.56% | 31.68% | 30.64% | 36.42% | 36.12% |
| Operating Profit Margin | 26.97% | 25.35% | 28.49% | 31.63% | 30.78% |
| Pretax Profit Margin | 20.98% | 28.46% | 27.39% | 32.84% | 32.53% |
| Net Profit Margin | 17.69% | 76.75% | 27.99% | 28.28% | 28.73% |
| Continuous Operations Profit Margin | 17.40% | 25.66% | 24.35% | 28.28% | 28.73% |
| Net Income Per EBT | 84.33% | 269.66% | 102.19% | 86.11% | 88.31% |
| EBT Per EBIT | 77.80% | 112.29% | 96.15% | 103.82% | 105.69% |
| Return on Assets (ROA) | 7.84% | 31.98% | 14.98% | 18.35% | 17.68% |
| Return on Equity (ROE) | 10.38% | 41.75% | 21.09% | 26.21% | 25.76% |
| Return on Capital Employed (ROCE) | 13.77% | 11.94% | 17.47% | 23.42% | 21.56% |
| Return on Invested Capital (ROIC) | 11.40% | 10.74% | 15.49% | 20.09% | 18.97% |
| Return on Tangible Assets | 9.94% | 41.32% | 17.94% | 22.24% | 21.44% |
| Earnings Yield | 2.15% | 9.43% | 3.03% | 3.30% | 1.86% |
| Efficiency Ratios | |||||
| Receivables Turnover | 6.65 | 7.48 | 6.05 | 7.70 | 7.87 |
| Payables Turnover | 5.83 | 5.66 | 5.56 | 5.78 | 5.99 |
| Inventory Turnover | 1.18 | 1.03 | 1.15 | 1.33 | 1.69 |
| Fixed Asset Turnover | 3.17 | 3.05 | 2.99 | 3.12 | 3.19 |
| Asset Turnover | 0.44 | 0.42 | 0.54 | 0.65 | 0.62 |
| Working Capital Turnover Ratio | 1.25 | 1.43 | 2.04 | 2.55 | 2.41 |
| Cash Conversion Cycle | 302.08 | 339.27 | 312.59 | 258.05 | 201.86 |
| Days of Sales Outstanding | 54.87 | 48.81 | 60.33 | 47.41 | 46.38 |
| Days of Inventory Outstanding | 309.79 | 354.94 | 317.92 | 273.78 | 216.37 |
| Days of Payables Outstanding | 62.58 | 64.48 | 65.66 | 63.14 | 60.89 |
| Operating Cycle | 364.66 | 403.75 | 378.25 | 321.19 | 262.75 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 2.73 | 0.91 | 1.48 | 1.97 | 2.78 |
| Free Cash Flow Per Share | 2.28 | 0.49 | 1.04 | 1.54 | 2.25 |
| Dividend Paid and CapEx Coverage Ratio | 6.13 | 2.15 | 3.36 | 4.60 | 5.25 |
| Capital Expenditure Coverage Ratio | 6.13 | 2.15 | 3.36 | 4.60 | 5.25 |
| Operating Cash Flow Coverage Ratio | 2.26 | 0.77 | 1.31 | 1.76 | 2.51 |
| Operating Cash Flow to Sales Ratio | 0.26 | 0.10 | 0.18 | 0.23 | 0.33 |
| Free Cash Flow Yield | 2.68% | 0.66% | 1.36% | 2.06% | 1.74% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 46.33 | 10.61 | 32.99 | 30.35 | 53.72 |
| Price-to-Sales (P/S) Ratio | 8.22 | 8.13 | 9.23 | 8.58 | 15.43 |
| Price-to-Book (P/B) Ratio | 4.82 | 4.43 | 6.96 | 7.95 | 13.84 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 37.34 | 152.63 | 73.49 | 48.44 | 57.58 |
| Price-to-Operating Cash Flow Ratio | 31.25 | 81.59 | 51.64 | 37.91 | 46.62 |
| Price-to-Earnings Growth (PEG) Ratio | -0.63 | 0.05 | -5.41 | 14.63 | 0.65 |
| Enterprise Value Multiple | 33.31 | 24.32 | 29.85 | 23.52 | 42.63 |
| Enterprise Value | 47.62B | 41.90B | 45.81B | 46.11B | 80.58B |
| EV to EBITDA | 33.31 | 24.32 | 29.85 | 23.52 | 42.63 |
| EV to Sales | 7.85 | 7.70 | 9.14 | 8.57 | 15.40 |
| EV to Free Cash Flow | 35.67 | 144.54 | 72.78 | 48.36 | 57.46 |
| EV to Operating Cash Flow | 29.85 | 77.27 | 51.14 | 37.85 | 46.52 |
| Tangible Book Value Per Share | 12.72 | 11.89 | 8.53 | 7.04 | 6.97 |
| Shareholders’ Equity Per Share | 17.68 | 16.73 | 10.96 | 9.38 | 9.36 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.17 | 0.10 | 0.11 | 0.14 | 0.12 |
| Revenue Per Share | 10.38 | 9.10 | 8.26 | 8.70 | 8.39 |
| Net Income Per Share | 1.84 | 6.98 | 2.31 | 2.46 | 2.41 |
| Tax Burden | 0.84 | 2.70 | 1.02 | 0.86 | 0.88 |
| Interest Burden | 1.00 | 0.99 | 0.99 | 0.99 | 0.99 |
| Research & Development to Revenue | 0.18 | 0.19 | 0.19 | 0.18 | 0.17 |
| SG&A to Revenue | 0.34 | 0.33 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 |
| Income Quality | 1.49 | 0.13 | 0.64 | 0.80 | 1.15 |
Currency in USD
